H. Lundbeck A/S
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HLBBF research report →
Companywww.lundbeck.com
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia.
- CEO
- Charl van Zyl
- IPO
- 2022
- Employees
- 5,707
- HQ
- Valby, DK
Price Chart
Valuation
- Market Cap
- $5.68B
- P/E
- 11.11
- P/S
- 1.31
- P/B
- 1.60
- EV/EBITDA
- 5.71
- Div Yield
- 2.78%
Profitability
- Gross Margin
- 78.95%
- Op Margin
- 27.86%
- Net Margin
- 14.71%
- ROE
- 14.81%
- ROIC
- 11.62%
Growth & Income
- Revenue
- $24.30B · 10.42%
- Net Income
- $3.18B · 1.33%
- EPS
- $3.21 · 1.26%
- Op Income
- $6.33B
- FCF YoY
- 56.98%
Performance & Tape
- 52W High
- $7.55
- 52W Low
- $4.42
- 50D MA
- $6.80
- 200D MA
- $6.24
- Beta
- 0.26
- Avg Volume
- 140
Get TickerSpark's AI analysis on HLBBF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our HLBBF Coverage
We haven't published any research on HLBBF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HLBBF Report →